NEWS
NEWS
ReacX Pharmaceuticals Initiates Nalmefene Phase I Clinical Study
January 21, 2026
FOR IMMEDIATE RELEASE SOUTH SAN FRANCISCO, CA, UNITED STATES – January 21, 2026 — ReacX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of long-term treatments for substance
REACX PHARMACEUTICALS AWARDED $10.35 MILLION GRANT TO ADVANCE NALMEFENE IMPLANT FOR OPIOID RELAPSE PREVENTION
February 3, 2025
Implant to use the Company’s proprietary ProNeura™ drug delivery system. February 3, 2025 – ReacX Pharmaceuticals, Inc. (“ReacX” or the “Company”), a company focused on developing and marketing pharmaceutical treatments